MedTrace Logo

Inositol in Letrozol Resistant PCOS Women

NCT07585396 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-05-18

No results posted yet for this study

Summary

Polycystic ovary syndrome (PCOS),is a complex neuro-endocrine disorder affecting approximately 5% to 10% of women in reproductive age.Inositols are considered insulin sensitizers, as they modulate the members of insulin signaling pathways.Thiss study compares between the effect of inositol and metformin in letrozol resistant PCOS women.

Conditions

  • Polycystic Ovary Syndrome
  • Letrozol Resistant

Interventions

DRUG

Myoinositol

Combined myoinositol \& Dchiroinositol twice daily plus letrozole for 3 months

DRUG

Metformin

Metformin 500mg twice daily plus letrozole for 3 months

Sponsors & Collaborators

  • Kafrelsheikh University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-10
Primary Completion
2026-05-10
Completion
2026-05-11
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07585396 on ClinicalTrials.gov